{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T19:46:25Z","timestamp":1762026385631,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":709,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41379-020-00669-7","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T09:32:54Z","timestamp":1599730374000},"page":"327-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma"],"prefix":"10.1016","volume":"34","author":[{"given":"Suyang","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zimu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7110-3814","authenticated-orcid":false,"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergej N.","family":"Konoplev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-0523","authenticated-orcid":false,"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-3898","authenticated-orcid":false,"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa","family":"Khanlari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet E.","family":"Manasanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-020-00669-7_bib1","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00669-7_bib2","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1038\/s41379-020-00669-7_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1038\/s41379-020-00669-7_bib4","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"10.1038\/s41379-020-00669-7_bib5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.leukres.2013.09.025","article-title":"Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications","volume":"37","author":"Bahmanyar","year":"2013","journal-title":"Leuk Res"},{"key":"10.1038\/s41379-020-00669-7_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bcmd.2014.05.006","article-title":"Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders","volume":"53","author":"Stella","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"10.1038\/s41379-020-00669-7_bib7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.humpath.2011.07.013","article-title":"Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with bortezomib","volume":"43","author":"Chen","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1038\/s41379-020-00669-7_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/bmt.2009.107","article-title":"1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"45","author":"Chang","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1038\/s41379-020-00669-7_bib9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3324\/haematol.2010.022210","article-title":"CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma","volume":"95","author":"Chang","year":"2010","journal-title":"Haematologica"},{"key":"10.1038\/s41379-020-00669-7_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2141.2007.06750.x","article-title":"Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma","volume":"139","author":"Chang","year":"2007","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1038\/s41379-020-00669-7_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"key":"10.1038\/s41379-020-00669-7_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/10428194.2018.1485908","article-title":"High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes","volume":"60","author":"Hu","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/s41379-020-00669-7_bib13","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","article-title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival","volume":"17","author":"Boyd","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-020-00669-7_bib14","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.bbmt.2016.09.003","article-title":"Outcome of patients with multiple myeloma and CKS1B gene amplification after autologous hematopoietic stem cell transplantation","volume":"22","author":"Bock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1038\/s41379-020-00669-7_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1038\/s41379-020-00669-7_bib16","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"key":"10.1038\/s41379-020-00669-7_bib17","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/modpathol.2017.63","article-title":"Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion","volume":"30","author":"Hao","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-00669-7_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/modpathol.2017.3","article-title":"Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience","volume":"30","author":"Carballo-Zarate","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-00669-7_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5858\/arpa.2012-0209-OA","article-title":"Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms","volume":"137","author":"Lu","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-020-00669-7_bib20","first-page":"1425","article-title":"High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1","volume":"34","author":"Westbrook","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1038\/s41379-020-00669-7_bib21","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"10.1038\/s41379-020-00669-7_bib22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","article-title":"Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy","volume":"16","author":"Nemec","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1038\/s41379-020-00669-7_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.105","article-title":"Over-expression of CKS1B activates both MEK\/ERK and JAK\/STAT3 signaling pathways and promotes myeloma cell drug-resistance","volume":"1","author":"Shi","year":"2010","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-020-00669-7_bib24","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"10.1038\/s41379-020-00669-7_bib25","doi-asserted-by":"crossref","first-page":"e1132","DOI":"10.1634\/theoncologist.2019-0132","article-title":"1q21 gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: a multicenter study in China","volume":"24","author":"Li","year":"2019","journal-title":"Oncologist"},{"key":"10.1038\/s41379-020-00669-7_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"Sawyer","year":"2011","journal-title":"Cancer Genet"},{"key":"10.1038\/s41379-020-00669-7_bib27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"10.1038\/s41379-020-00669-7_bib28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"10.1038\/s41379-020-00669-7_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2013.088211","article-title":"Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value","volume":"99","author":"An","year":"2014","journal-title":"Haematologica"},{"key":"10.1038\/s41379-020-00669-7_bib30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"key":"10.1038\/s41379-020-00669-7_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-1759(01)00389-1","article-title":"Flow cytometric DNA-quantification of three-color immunophenotyped cells for subpopulation specific determination of aneuploidy and proliferation","volume":"253","author":"Oelschlaegel","year":"2001","journal-title":"J Immunol Methods"},{"key":"10.1038\/s41379-020-00669-7_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","article-title":"ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma","volume":"32","author":"Marchesini","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1038\/s41379-020-00669-7_bib33","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-00669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-00669-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222006743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222006743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-00669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:39:47Z","timestamp":1760229587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222006743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0893395222006743"],"URL":"https:\/\/doi.org\/10.1038\/s41379-020-00669-7","relation":{},"ISSN":["0893-3952"],"issn-type":[{"type":"print","value":"0893-3952"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-020-00669-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}